| 臺大學術典藏 |
2021-02-02T02:21:18Z |
Consensus of gastroesophageal reflux disease in Taiwan with endoscopy-based approach covered by National Health Insurance
|
Sheu B.-S.; Chiu C.-T.; Lee Y.-C.; Chang C.-Y.; Wu D.-C.; Liou J.-M.; MING-SHIANG WU; Chang W.-L.; Wu C.-Y.; Lin J.-T. |
| 臺大學術典藏 |
2021-02-02T02:21:17Z |
Associations of circulating gut hormone and adipocytokine levels with the spectrum of gastroesophageal reflux disease
|
Tseng P.-H.; Yang W.-S.; Liou J.-M.; Lee Y.-C.; Wang H.-P.; Lin J.-T.; MING-SHIANG WU |
| 臺大學術典藏 |
2021-02-02T02:21:17Z |
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
|
Fang Y.-J.; Liou J.-M.; Chen C.-C.; Lee J.-Y.; Hsu Y.-C.; Chen M.-J.; Tseng P.-H.; Chen C.-C.; Chang C.-Y.; Yang T.-H.; Chang W.-H.; Wu J.-Y.; Wang H.-P.; Luo J.-C.; Lin J.-T.; Shun C.-T.; MING-SHIANG WU |
| 臺大學術典藏 |
2021-02-02T02:21:15Z |
Prevention of gastric cancer by helicobacter pylori eradication: Current evidence and future prospects
|
Liou J.-M.; Lin J.-T.; MING-SHIANG WU |
| 臺大學術典藏 |
2021-02-02T02:21:14Z |
Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection
|
Chen M.-J.; Liou J.-M.; Chen C.-C.; Lee Y.-C.; Chang C.-Y.; Wu J.-Y.; Bair M.-J.; Lin J.-T.; MING-SHIANG WU |
| 臺大學術典藏 |
2021-02-02T02:21:14Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; Chen C.-C.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; MING-SHIANG WU |
| 臺大學術典藏 |
2021-02-02T02:21:11Z |
Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation
|
Lee T.-Y.; Lin J.-T.; Zeng Y.-S.; Chen Y.-J.; MING-SHIANG WU; Wu C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:21:10Z |
Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients
|
Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; MING-SHIANG WU; Kao J.-H.; Wang W.-L.; Yang T.-H.; Wang C.-S.; Chiang M.-F.; Chen C.-C.; Fang Y.-J.; Hung H.-W.; Wu C.-Y.; Lin J.-T. |
| 臺大學術典藏 |
2021-02-02T02:21:10Z |
Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection
|
Chen P.-Y.; MING-SHIANG WU; Chen C.-Y.; Bair M.-J.; Chou C.-K.; Lin J.-T.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:21:08Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; MING-SHIANG WU; the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:21:08Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; Chen C.-C.; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; MING-SHIANG WU; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:21:07Z |
Treatment of Helicobacter pylori infection: Where are we now?
|
Liou J.-M.; MING-SHIANG WU; Lin J.-T. |
| 臺大學術典藏 |
2021-02-02T02:21:06Z |
Bismuth and Non-bismuth Quadruple Therapy for Helicobacter pylori Eradication: Time to Make the Switch in Clinical Practice?
|
Liou J.-M.; Lin J.-T.; MING-SHIANG WU |
| 臺大學術典藏 |
2021-02-02T02:21:05Z |
Distinct Clinicopathological Features and Prognosis of Helicobacter pylori Negative Gastric Cancer
|
Tsai K.-F.; Liou J.-M.; Chen M.-J.; Chen C.-C.; Kuo S.-H.; Lai I.-R.; Yeh K.-H.; Lin M.-T.; Wang H.-P.; Cheng A.-L.; Lin J.-T.; Shun C.-T.; MING-SHIANG WU |
| 臺大學術典藏 |
2021-02-02T02:21:03Z |
Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale
|
Sheu B.-S.; MING-SHIANG WU; Chiu C.-T.; Lo J.-C.; Wu D.-C.; Liou J.-M.; Wu C.-Y.; Cheng H.-C.; Lee Y.-C.; Hsu P.-I.; Chang C.-C.; Chang W.-L.; Lin J.-T. |
| 臺大學術典藏 |
2021-02-02T02:21:02Z |
Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy
|
Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; MING-SHIANG WU; Yang T.-H.; Kao J.-H.; Chen C.-C.; Tseng C.-H.; Tai C.-M.; Lin C.-W.; Wu C.-Y.; Lin J.-T. |
| 臺大學術典藏 |
2021-02-02T02:21:01Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; MING-SHIANG WU; Chen C.-C.; Chen C.-C.; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:21:01Z |
The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease
|
Lee T.-Y.; Wu J.-C.; Yu S.-H.; Lin J.-T.; MING-SHIANG WU; Wu C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:21:01Z |
Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis
|
Kuo Y.-T.; Liou J.-M.; El-Omar E.M.; Wu J.-Y.; Leow A.H.R.; Goh K.L.; Das R.; Lu H.; Lin J.-T.; Tu Y.-K.; Yamaoka Y.; MING-SHIANG WU; for the, Asian Pacific Alliance on Helicobacter; Microbiota |
| 臺大學術典藏 |
2021-02-02T02:21:00Z |
Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy
|
Chien N.-H.; Huang Y.-T.; Wu C.-Y.; Chang C.-Y.; MING-SHIANG WU; Kao J.-H.; Mo L.-R.; Tai C.-M.; Lin C.-W.; Yang T.-H.; Lin J.-T.; Hsu Y.-C. |
| 臺大學術典藏 |
2021-02-02T02:20:59Z |
First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: A systematic review and network meta-analysis
|
Yeo Y.H.; Shiu S.-I.; Ho H.J.; Zou B.; Lin J.-T.; MING-SHIANG WU; Liou J.-M.; Wu C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:20:59Z |
Prior gastroscopy and mortality in patients with gastric cancer: a matched retrospective cohort study
|
Leung W.K.; Ho H.J.; Lin J.-T.; MING-SHIANG WU; Wu C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:20:57Z |
Survey of the adherence to the consensus of gastroesophageal reflux disease before and after the implementation course
|
Liou J.-M.; Sheu B.-S.; Lee Y.-C.; Cheng H.-C.; Chang W.-L.; Wu D.-C.; Hsu P.-I.; Wu C.-Y.; MING-SHIANG WU; Chiu C.-T.; Lin J.-T. |
| 臺大學術典藏 |
2021-02-02T02:20:56Z |
Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir
|
Hsu Y.-C.; Ho H.-J.; Lee T.-Y.; Huang Y.-T.; MING-SHIANG WU; Lin J.-T.; Wu C.-Y.; El-Serag H.B. |
| 臺大學術典藏 |
2021-02-02T02:20:55Z |
Effect of Nucleos(t)ide Analogue Therapy on Risk of Intrahepatic Cholangiocarcinoma in Patients With Chronic Hepatitis B
|
Lee T.-Y.; Hsu Y.-C.; Yu S.-H.; Lin J.-T.; MING-SHIANG WU; Wu C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:20:54Z |
Nutrition therapy in esophageal cancer—Consensus statement of the Gastroenterological Society of Taiwan
|
Chen M.-J.; Wu I.-C.; Chen Y.-J.; Wang T.-E.; Chang Y.-F.; Yang C.-L.; Huang W.-C.; Chang W.-K.; Sheu B.-S.; MING-SHIANG WU; Lin J.-T.; Chu C.-H. |
| 臺大學術典藏 |
2021-02-02T02:20:54Z |
Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B
|
Hsu Y.-C.; Yip T.C.-F.; Ho H.J.; Wong V.W.-S.; Huang Y.-T.; El-Serag H.B.; Lee T.-Y.; MING-SHIANG WU; Lin J.-T.; Wong G.L.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:20:53Z |
The implementation of the consensus on the management of Helicobacter pylori and barriers to consensus
|
Cheng H.-C.; Liou J.-M.; Luo J.-C.; Chiu C.-T.; MING-SHIANG WU; Lee Y.-C.; Wu C.-Y.; Wu D.-C.; Hsu P.-I.; Chang C.-C.; Chang W.-L.; Lin J.-T.; Sheu B.-S. |
| 臺大學術典藏 |
2021-02-02T02:20:53Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; MING-SHIANG WU; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:20:53Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; MING-SHIANG WU; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; MING-SHIANG WU; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:20:52Z |
Systematic review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection
|
Chen M.-J.; Chen C.-C.; Chen Y.-N.; Chen C.-C.; Fang Y.-J.; Lin J.-T.; MING-SHIANG WU; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:20:51Z |
Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B
|
Tseng C.-H.; Hsu Y.-C.; Chang C.-Y.; Tseng T.-C.; MING-SHIANG WU; Lin J.-T.; Kao J.-H. |
| 臺大學術典藏 |
2021-02-02T02:20:49Z |
Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk
|
Hsu Y.-C.; Nguyen M.H.; Mo L.-R.; MING-SHIANG WU; Yang T.-H.; Chen C.-C.; Tseng C.-H.; Tai C.-M.; Wu C.-Y.; Lin J.-T.; Tanaka Y.; Chang C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:20:49Z |
Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication
|
Yeo Y.H.; Hsu C.-C.; Lee C.-C.; Ho H.J.; Lin J.-T.; MING-SHIANG WU; Liou J.-M.; Wu C.-Y.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T02:20:47Z |
Corrigendum to “Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B” [J Hepatol 69 (2018) 278–285](S0168827818301703)(10.1016/j.jhep.2018.02.032)
|
Hsu Y.-C.; Yip T.C.-F.; Ho H.J.; Wong V.W.-S.; Huang Y.-T.; El-Serag H.B.; Lee T.-Y.; MING-SHIANG WU; Lin J.-T.; Wong G.L.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:20:46Z |
Serum pepsinogen as a predictor for gastric cancer death A 16-year community-based cohort study
|
Chiang T.-H.; Chiu S.Y.-H.; Chen S.L.-S.; Yen A.M.-F.; Fann J.C.-Y.; Liu C.-Y.; Chou C.-K.; Chiu H.-M.; Shun C.-T.; MING-SHIANG WU; Lin J.-T.; Lee Y.-C.; Chen T.H.-H.; Lin M.-W. |
| 臺大學術典藏 |
2021-02-02T02:20:45Z |
Association of Daily Aspirin Therapy with Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
|
Lee T.-Y.; Hsu Y.-C.; Tseng H.-C.; Yu S.-H.; Lin J.-T.; MING-SHIANG WU; Wu C.-Y. |
| 臺大學術典藏 |
2021-02-02T02:20:43Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; MING-SHIANG WU; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-02-02T00:47:06Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.;Hsu C.-H.;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Yeong-Shiau Pu;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Hsieh C.-Y.; Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; YEONG-SHIAU PU; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-01-28T01:07:03Z |
Five-drug combination chemotherapy (FAPEL) for advanced gastric cancer: A pilot study
|
KUN-HUEI YEH; Cheng A.-L.; Chen Y.-C.; Chen B.-R.; Lee W.-J.; Lin J.-T.; Lee P.-H.; Chang K.-J.; Wang C.-H.; Wang T.-H. |
| 臺大學術典藏 |
2021-01-28T01:07:01Z |
Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers
|
Hsu C.-H.;Kun-Huei Yeh;Chen L.-T.;Liu J.M.;Jan C.-M.;Lin J.-T.;Chen Y.-C.;Cheng A.-L.; Hsu C.-H.; KUN-HUEI YEH; Chen L.-T.; Liu J.M.; Jan C.-M.; Lin J.-T.; Chen Y.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:59Z |
Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers
|
KUN-HUEI YEH; Chen C.-L.; Shun C.-T.; Lin J.-T.; Lee W.-J.; Lee P.-H.; Chen Y.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:58Z |
Detection of circulating cancer cells by nested reverse transcription-polymerase chain reaction of cytokeratin-19 (K19) - Possible clinical significance in advanced gastric cancer
|
KUN-HUEI YEH; Chen Y.-C.; Yeh S.-H.; Chen C.-P.; Lin J.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:58Z |
Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) - A very effective regimen with good patients' compliance for advanced gastric cancer
|
Cheng A.-L.; KUN-HUEI YEH; Lin J.-T.; Hsu C.; Liu M.-Y. |
| 臺大學術典藏 |
2021-01-28T01:06:57Z |
High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy
|
KUN-HUEI YEH; Shun C.-T.; Chen C.-L.; Lin J.-T.; Lee W.-J.; Lee P.-H.; Chen Y.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:55Z |
Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy
|
Kun-Huei Yeh;Shun C.-T.;Chen C.-L.;Lin J.-T.;Lee W.-J.;Lee P.-H.;Chen Y.-C.;Cheng A.-L.; KUN-HUEI YEH; Shun C.-T.; Chen C.-L.; Lin J.-T.; Lee W.-J.; Lee P.-H.; Chen Y.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:55Z |
Concurrent chemoradiotherapy for locally advanced esophageal cancer - A pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil
|
Hsu C.-H.;Kun-Huei Yeh;Lui L.T.;Lee Y.-C.;Bu C.-F.;Wang H.-P.;Lin J.-T.;Cheng A.-L.; Hsu C.-H.; KUN-HUEI YEH; Lui L.T.; Lee Y.-C.; Bu C.-F.; Wang H.-P.; Lin J.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:49Z |
Expression of CD86 and increased inflitration of NK cells are associated with Helicobacter pylori-dependent state of early stage high-grade gastric MALT lymphoma
|
Kuo S.-H.;Chen L.-T.;Chen C.-L.;Doong S.-L.;Kun-Huei Yeh;Wu M.-S.;Mao T.-L.;Hsu H.-C.;Wang H.-P.;Lin J.-T.;Cheng A.-L.; Kuo S.-H.; Chen L.-T.; Chen C.-L.; Doong S.-L.; KUN-HUEI YEH; Wu M.-S.; Mao T.-L.; Hsu H.-C.; Wang H.-P.; Lin J.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:49Z |
Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas
|
Kuo S.-H.;Chen L.-T.;Kun-Huei Yeh;Wu M.-S.;Hsu H.-C.;Yeh P.-Y.;Mao T.-L.;Chen C.-L.;Doong S.-L.;Lin J.-T.;Cheng A.-L.; Kuo S.-H.; Chen L.-T.; KUN-HUEI YEH; Wu M.-S.; Hsu H.-C.; Yeh P.-Y.; Mao T.-L.; Chen C.-L.; Doong S.-L.; Lin J.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:48Z |
Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21 )
|
Kun-Huei Yeh;Kuo S.-H.;Chen L.-T.;Mao T.-L.;Doong S.-L.;Wu M.-S.;Hsu H.-C.;Tzeng Y.-S.;Chen C.-L.;Lin J.-T.;Cheng A.-L.; KUN-HUEI YEH; Kuo S.-H.; Chen L.-T.; Mao T.-L.; Doong S.-L.; Wu M.-S.; Hsu H.-C.; Tzeng Y.-S.; Chen C.-L.; Lin J.-T.; Cheng A.-L. |
